Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial-Reference-Cited by-同舟云学术

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Published:2020-10-21 Issue:4 Volume:27 Page:1003-1011
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Xu Jianming^ORCID,Shen Jie,Gu Shanzhi,Zhang Yun,Wu Lihua,Wu Jian,Shao Guoliang,Zhang Yanqiao,Xu Li^ORCID,Yin Tao,Liu Jingfeng,Ren Zhenggang,Xiong Jianping,Mao Xianhai,Zhang Ling,Yang Jiayin,Li Lequn,Chen Xiaoming,Wang Zhiming,Gu Kangsheng,Chen Xi,Pan Zhanyu,Ma Kuansheng,Zhou Xinmin,Yu Zujiang,Li Enxiao,Yin Guowen,Zhang Xiao,Wang Shuni,Wang Quanren

Funder

Jiangsu Hengrui Medicine Co., Ltd

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 422 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma;Journal of Ethnopharmacology;2024-11

2. ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism;Clinics and Research in Hepatology and Gastroenterology;2024-10

3. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

4. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma;Molecular Cancer;2024-09-06

5. A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma;Targeted Oncology;2024-09